RA Patient Priorities And Motivators For Clinical Trial Involvement
Two new initiatives designed to improve the management of rheumatoid arthritis through patient participation were presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.
Medivation Initiates Second Pivotal Phase 3 Trial Of Dimebon trade; In Patients With Alzheimer's Disease
Medivation, Inc. (NASDAQ: MDVN) announced it has initiated dosing of patients in its second pivotal Phase 3 trial of the investigational drug Dimebon™ in patients with mild-to-moderate Alzheimer's disease (AD). The international, double-blind, placebo-controlled safety and efficacy study of oral Dimebon is known as the CONNECTION study.
Positive Clinical Data For PBI-1402 Presented At The Annual Congress Of The European Hematology Association
ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") presented results on its orally-active PBI-1402 compound in clinical trial in patients with chemotherapy-induced anemia ("CIA") at the 13th Congress of the European Hematology Association held in Copenhagen, Denmark this week.
U.S. FDA Approves Requip reg; XL trade;, The First And Only Oral Once-daily Non-ergot Dopamine Agonist For Parkinson's Disease
GlaxoSmithKline announced the approval of Requip XL™ (ropinirole extended-release tablets) in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Itis the first and only oral once-daily non-ergot dopamine agonist indicated for Parkinson's disease.
Transfer Of Learning Traced To Areas Of The Brain
Practice makes perfect, but a question that still remains a mystery is why it is so difficult to transfer learning from a trained to an untrained task? Why are we no better at remembering faces when we have been training our memory for words? Scientists at Umea University and Karolinska Institutet in Sweden now show in the journal Science that the answer lies in the brain areas activated by each task.
Treating Pain Effectively - New Study Results Confirm Improved Gastrointestinal Tolerability Of Tapentadol
Results from two phase III clinical studies of tapentadol immediate release tablets (IR) suggest a significantly improved gastrointestinal tolerability(1) as well as safety(2) profile compared to oxycodone HCl IR. The data were presented by the German pharmaceutical company Grunenthal at this year's Annual Congress of the European League against Rheumatism (EULAR, June 11-14, Paris, France).
Nicotine Addiction: Prevalence And Treatment
A Seminar released on June 13, 2008 in The Lancetdiscusses nicotine addiction, and the potential for reducing itsdisease burden and death toll by improving public knowledge and usingtreatments individual to patients. This includes the potential creationof an antinicotine vaccine.
New Hope For COPD Patients In Mucolytic Carbocisteine
The worsening of symptoms in patients with chronic obstructivepulmonary disease (COPD) can be curtailed by using carbocisteine, according toan article released on Jun 16, 2008 in The Lancet. Carbocisteine is a mucolytic drug, which breaks down mucus in the bodyso that it can be more easily cleared from the body.
Groundbreaking Depression Research Tested In Real-World Setting
UT Southwestern Medical Center psychiatry researchers have taken what they learned from their groundbreaking research on treating depression and are applying it to real-world clinical settings.The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study was the largest ever on the treatment of major depressive disorder and is considered a benchmark in the field of depression research.
Exelixis Presents Clinical Data Supporting The Safety And Initial Clinical Activity Of XL228 In Chronic And Acute Leukemia
Exelixis, Inc. (Nasdaq: EXEL) reported preliminary phase 1 data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ALL) who are resistant to or intolerant of the approved BCR-ABL inhibitors imatinib and dasatinib.